Used primarily to reduce elevated lipid levels in the blood, particularly triglycerides and low-density lipoprotein (LDL) cholesterol, while increasing high-density lipoprotein (HDL) cholesterol. It is prescribed for patients with hyperlipidemia or mixed dyslipidemia, often as part of a broader cardiovascular risk reduction strategy. Fenofibric acid activates peroxisome proliferator-activated receptor alpha (PPARα), which enhances the breakdown of fatty acids and lipoproteins in the liver and bloodstream. It is commonly used when statins are not sufficient or tolerated, and may help reduce the risk of pancreatitis in individuals with very high triglyceride levels.